Evidence map›Paper›PMID 41935577›Full record

ArticleVirologica Sinica2026

Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes.

Yuelin Wang, Wei Dou, Yingying Chen, Ke Liu, Mengjun Li, Tyuji Hoshino, Yushan Jiang, Vladislav Victorovich Khrustalev, Alexey V Churov, Alexander N Orekhov and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuelin WangBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China; National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China.
Wei DouBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Yingying ChenBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China; School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Ke LiuBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Mengjun LiBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Tyuji HoshinoGraduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan.
Yushan JiangBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Vladislav Victorovich KhrustalevDepartment of General Chemistry, Belarusian State Medical University, Minsk 220045, Belarus.
Alexey V ChurovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow 125315, Russia.
Alexander N OrekhovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow 125315, Russia.
Wei ZhaoBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China. Electronic address: zhaowei@smu.edu.cn.
Ling LiBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China; School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address: liling@smu.edu.cn.
Yang YangNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China. Electronic address: young@mail.sustech.edu.cn.
Chenguang ShenBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education, Guangzhou 510515, China. Electronic address: a124965468@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenoviruses (HAdVs), particularly subgroup B serotypes HAdV-3 and HAdV-55, are associated with severe respiratory disease and currently lack targeted therapies. While neutralizing monoclonal antibodies (nMAbs) offer promising therapeutic potential, the specific nMAbs targeting these serotypes remain poorly characterized. Therefore, this study aimed to generate and evaluate the efficacy of serotype-specific nMAbs against HAdV-3 and HAdV-55. Mice were immunized with HAdV-3 virions, HAdV-55 virions, or recombinant fiber knob proteins (HAdV-55/-7) for the generation of serotype-specific nMAbs, and their efficacy was systematically evaluated using in vitro assays and an in vivo tree shrew model. Through comprehensive screening, eleven MAbs were identified with specificity against HAdV-3 (six clones) or HAdV-55/-7 fiber knob (five clones). Four nMAbs exhibited potent neutralizing activity: 13F12 (half-maximal inhibitory concentration, IC

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAnimalsFemaleHumansMiceMice, Inbred BALB CNeutralization TestsSerogroupAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntiviral therapyB subgroup serotypesHuman adenovirus (HAdV)Monoclonal antibodyNeutralizing antibodyRespiratory infection

Identifiers

PMID41935577
PMCPMC13215954

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.